Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Lechuga-Ballesteros, V. Joshi, M. Sommerville, M. Golden, R. Vehring, B. Noga, H. Cummings, R. Schultz, C. Orevillo, C. Reisner, S. Dwivedi (Redwood City, Raleigh, Morristown, United States Of America). Highly efficient dual and triple combination therapies with no coformulation effect for treatment of COPD. Eur Respir J 2012; 40: Suppl. 56, 2152

Member's Comments

No comment yet.

Related content which might interest you: Lack of clinically relevant differences between combination therapy and monotherapy in COPD Source: Eur Respir J 2014; 43: 1204-1205 Year: 2014 Lack of clinically relevant differences between combination therapy and monotherapy in COPD Source: Eur Respir J 2014; 43: 1204 Year: 2014 Eliminating in-vitro drug-drug interactions in dual and triple fixed-dose combination therapies using a novel cosuspension metered dose inhaler platform Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Chinese subgroup results from a study comparing single-inhaler triple therapy with dual therapy in COPD Source: International Congress 2017 – COPD management Year: 2017 Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma? Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Comparison of efficacy and safety of fixed-dose combination regimen versus separate drugs for treatment of tuberculosis Source: International Congress 2019 – Insights into paediatric bronchology Year: 2019 Triple therapy versus dual bronchodilation and long-acting ß-agonists/inhaled corticosteroids in COPD: accumulating evidence from network meta-analyses Source: International Congress 2019 – Therapeutic breakthrough Year in review Year: 2019 Combination therapy with sotatercept analog RAP-011 is superior to sildenafil alone in severe experimental PAH and RAP-011 benefits persist after treatment cessation Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 GRC39815-A novel inhaled ROR?t inhibitor as a potential first in class treatment option for COPD Source: Virtual Congress 2021 – Pharmacology of airway diseases: clinical and laboratory studies Year: 2021 Preventing clinically important deterioration with single-inhaler triple therapy in COPD Source: ERJ Open Res, 4 (4) 00047-2018; 10.1183/23120541.00047-2018 Year: 2018 An inhaled “bifunctional” dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD Source: Eur Respir J, 52 (5) 1801675; 10.1183/13993003.01675-2018 Year: 2018 The effectiveness of inhaled steroids as first-line therapy in the treatment of newly detected asthma Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001 Symptomatic burden of COPD for patients receiving dual or triple therapy Source: International Congress 2017 – Management of COPD Year: 2017 The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD Source: Breathe, 14 (4) 333; 10.1183/20734735.026418 Year: 2018 Long-acting bronchodilators and synergistic interaction: a challenge across the currently available LABA/LAMA combinations Source: International Congress 2018 – Studies on the mechanisms underlying airway disease Year: 2018 Comparison of anti-tuberculosis regimens using fixed dose combination versus single drugs Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010 Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001 Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 The response to combination therapy treatment regimens in severe/difficult-to-treat asthma Source: Eur Respir J 2008; 32: 1237-1242 Year: 2008 Inhaler preference comparing two alternative dual bronchodilator regimens Source: International Congress 2016 – Pulmonary drug delivery Year: 2016